- Home
- XERS vs XNCR Comparison
XERS vs XNCR Comparison
Compare XERS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- XNCR
- Stock Information
- Founded
- XERS 2005
- XNCR 1997
- Country
- XERS United States
- XNCR United States
- Employees
- XERS N/A
- XNCR N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- XERS Health Care
- XNCR Health Care
- Exchange
- XERS Nasdaq
- XNCR Nasdaq
- Market Cap
- XERS 628.7M
- XNCR 579.3M
- IPO Year
- XERS 2018
- XNCR 2013
- Fundamental
- Price
- XERS $4.51
- XNCR $8.54
- Analyst Decision
- XERS Strong Buy
- XNCR Buy
- Analyst Count
- XERS 6
- XNCR 7
- Target Price
- XERS $6.25
- XNCR $27.50
- AVG Volume (30 Days)
- XERS 2.1M
- XNCR 791.6K
- Earning Date
- XERS 08-07-2025
- XNCR 08-04-2025
- Dividend Yield
- XERS N/A
- XNCR N/A
- EPS Growth
- XERS N/A
- XNCR N/A
- EPS
- XERS N/A
- XNCR N/A
- Revenue
- XERS $222,551,000.00
- XNCR $127,228,000.00
- Revenue This Year
- XERS $35.03
- XNCR N/A
- Revenue Next Year
- XERS $18.31
- XNCR $28.84
- P/E Ratio
- XERS N/A
- XNCR N/A
- Revenue Growth
- XERS 29.88
- XNCR N/A
- 52 Week Low
- XERS $2.03
- XNCR $7.16
- 52 Week High
- XERS $6.07
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- XERS 46.97
- XNCR 44.94
- Support Level
- XERS $4.30
- XNCR $8.05
- Resistance Level
- XERS $4.79
- XNCR $10.20
- Average True Range (ATR)
- XERS 0.23
- XNCR 0.57
- MACD
- XERS -0.01
- XNCR -0.01
- Stochastic Oscillator
- XERS 25.93
- XNCR 31.40
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.